The recall should consider how to ensure that all parties comply with the terms of the agreements, such as .B inclusion of wholesale distributors in the Mah`s risk-based audit programme or the implementation of routine checks of wholesalers` pharmacovigilance activity, such as regular coordination of adverse event reports between the distributor and the Mah, which can detect discrepancies in the information exchanged.B. Power. Communicating Changes in Risk: Benefits to Healthcare Professionals (HCPs) and Patients is another important process in pharmacovigilance1. Raising awareness of the risks associated with products is fundamental to patient safety. One way to do this is to provide up-to-date product information (Summary of Product Characteristics (SmPC), Package Leaflet (PL) and Packaging). In addition, and according to the Pharmacovigilance Inspection Metrics Report of the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) (April 2016 – March 2017),3 key findings regarding the maintenance of safety baseline information increased significantly during the reference period. This section of the PVA should determine whether there will be a basic company data sheet and who will maintain it, as well as who is responsible for updating local CSMS. Another important aspect is confirmation of who will be responsible for communicating with regulators and how updates will be shared (both within partner companies and with the public/healthcare professionals). If the above is not sufficiently defined, even when the updates are complete, the information may not reach patients and healthcare professionals in all regions where the product is marketed. In addition, if the update is made by the regulatory authority that communicates with one of the parties, deadlines should be set to notify the other party, as well as a clause to manage disputes regarding the response to the regulator. It is useful to define this so that the most appropriate party (i.e. the mah or company present in the local area where the government request was made) can communicate effectively with the authority. According to GVP module I1; The collection, processing and management of individual safety reports (ICSRs) is an essential pharmacovigilance process.
It is therefore imperative that this be included in the PVA. In this section, there are important areas that need to be covered. First of all, it is necessary to define the type of cases collected by each partner (e.g. B post-marketing, clinical trials, registries, market studies) and whether serious and non-serious cases should be exchanged. .
